financetom
Business
financetom
/
Business
/
HubSpot Shares Climb After Strong Q3 Results: EPS Beat, Revenues Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HubSpot Shares Climb After Strong Q3 Results: EPS Beat, Revenues Beat
Nov 9, 2024 11:41 AM

HubSpot, Inc. ( HUBS ) shares are trading higher after the company reported its third-quarter results after Wednesday's closing bell. Here's a look at the details from the report. 

The Details: HubSpot ( HUBS ) reported quarterly earnings of $2.22 per share, which beat the analyst consensus estimate of $1.91. Quarterly revenue clocked in at $669.7 million which beat the analyst consensus estimate of $646.9 million and is an increase over sales of $557.55 million from the same period last year.

Subscription revenue was $654.7 million, up 20% year-over-year.

Professional services and other revenue was $15 million, up 28% year-over-year.

Customers grew to 238,128 at Sept. 30, 2024, up 23% from the prior year’s quarter.

Average Subscription Revenue Per Customer was $11,235 during the third quarter.

Read Next: What Does Trump’s Victory Mean For EV Giant Tesla And The Big 3 Automakers?

“[The] third quarter was another strong quarter of revenue growth, operating profit growth and customer growth,” said Yamini Rangan, CEO at HubSpot ( HUBS ).

“We hosted our annual INBOUND conference which was a huge success, showcasing over 200 new innovations, including the standout launches of Breeze and Breeze Intelligence. We are embedding AI across all our hubs and our entire platform to help SMBs grow. With our relentless focus on innovation with AI and solid momentum in the third quarter, I’m more confident than ever in HubSpot’s durable growth,” Rangan added.

Outlook: HubSpot ( HUBS ) sees fourth-quarter total revenue in the range of $672 million to $674 million and expects foreign exchange rates to have a one-point tailwind to fourth-quarter 2024 revenue growth. The company sees full-year 2024 total revenue in the range of $2.597 billion to $2.599 billion.

HUBS Price Action: According to Benzinga Pro, HubSpot ( HUBS ) shares are up 7.90% after-hours at $645 after gaining 3.37% during Wednesday’s regular trading session.

Read More: 

Trump’s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
S&P Global Closes ProntoNLP Acquisition
S&P Global Closes ProntoNLP Acquisition
Jan 6, 2025
08:17 AM EST, 01/06/2025 (MT Newswires) -- S&P Global ( SPGI ) said Monday it closed the acquisition of generative artificial intelligence tooling provider ProntoNLP on Dec. 31, 2024. Financial terms were not disclosed, the company said. ...
Regional Health Properties to Acquire SunLink Health Systems in All-Stock Deal
Regional Health Properties to Acquire SunLink Health Systems in All-Stock Deal
Jan 6, 2025
08:15 AM EST, 01/06/2025 (MT Newswires) -- Regional Health Properties ( RHE/PA ) and SunLink Health Systems ( SSY ) said Monday that they have agreed to merge in an all-stock deal. Regional Health shares were up more than 209% and SunLink Health ( SSY ) shares were over 16% higher in Monday's premarket activity. Under the terms of the...
Star Diamond Raising Up to $500,000 in Private Placement
Star Diamond Raising Up to $500,000 in Private Placement
Jan 6, 2025
08:18 AM EST, 01/06/2025 (MT Newswires) -- Star Diamond ( SHGDF ) said Monday that it is raising up to $500,000 in a non-brokered convertible note private placement. The company plans to use the proceeds for general working capital purposes as it continues discussions with possible investors to fund a pre-feasibility study for the Fort a la Corne kimberlites in...
Algernon Pharmaceuticals Receives U.S. Patent for Repirinast
Algernon Pharmaceuticals Receives U.S. Patent for Repirinast
Jan 6, 2025
08:20 AM EST, 01/06/2025 (MT Newswires) -- Algernon Pharmaceuticals ( AGNPF ) on Monday said it received a notice of allowance from the United States Patent and Trademark Office for Repirinast, the company's lead chronic kidney disease (CKD) drug. The company has corresponding patents in Japan and China and has applications pending in Europe and Canada. Repirinast is Algernon's lead...
Copyright 2023-2026 - www.financetom.com All Rights Reserved